NCT05749588 2026-04-16
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Fudan University
Phase 2 Recruiting
Clinical Trials
7 trialsNCT05582499 2025-08-22
FASCINATE-N
Fudan University
Phase 2 Recruiting
NCT05475678 2025-01-23
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
Henan Cancer Hospital
Phase 2 Recruiting
NCT05999149 2024-02-21
BCTOP-T-N01
Fudan University
Phase 3 Recruiting
NCT05760378 2024-02-06
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
Fudan University
Phase 3 Recruiting
NCT05447702 2023-05-22
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
West China Hospital
Phase 2 Recruiting
NCT04481763 2020-07-22
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
Jiangxi Provincial Cancer Hospital
Phase 1/2 Recruiting